Purpose: This study aimed to verify the safety of low-dose topiramate on language development in pediatric patients with migraine. Methods: Thirty newly diagnosed pediatric patients with migraine who needed topiramate were enrolled and assessed twice with standard language tests, including the Test of Language Problem Solving Abilities (TOPs), Receptive and Expressive Vocabulary Test, Urimal Test of Articulation and Phonology, and computerized speech laboratory analysis. Data were collected before treatment, and topiramate as monotherapy was sustained for at least 3 months. The mean follow-up period was 4.3 ± 2.7 months. The mean topiramate dosage was 0.9 mg/kg/day. Results: The patient's mean age was 144.1 ± 42.3 months (male-to-female ratio, 9:21). The values of all the language parameters of the TOPs were not changed significantly after the topiramate treatment as follows: Determine cause, from 15.0 ± 4.4 to 15.4 ± 4.8 (P>0.05); making inference, from 17.6 ± 5.6 to 17.5 ± 6.6 (P>0.05); predicting, from 11.5 ± 4.5 to 12.3 ± 4.0 (P>0.05); and total TOPs score, from 44.1 ± 13.4 to 45.3 ± 13.6 (P>0.05). The total mean length of utterance in words during the test de creased from 44.1 ± 13.4 to 45.3 ± 13.6 (P<0.05). The Receptive and Expressive Vocabulary Test results decreased from 97.7 ± 22.1 to 96.3 ± 19.9 months, and from 81.8 ± 23.4 to 82.3 ± 25.4 months, respectively (P>0.05). In the articulation and phonology validation in both groups, speech pitch and energy were not significant, and all the vowel test results showed no other significant values. Conclusion: No significant difference was found in the language-speaking ability between the patients; however, the number of vocabularies used decreased. Therefore, topiramate should be used cautiously for children with migraine.
Introduction
Migraine is one of the most serious primary headaches in children and occurs in up to 10.6 % of children aged 5-15 years 1) . Migraine attacks may have negative effects on every aspect of a child's quality of life, including daily activities, interactions with peers, and family dy namics 2, 3) . Therefore, many children with migraine who do not tolerate to conser vative treat ments or to nonsteroidal antiinflammatory drugs are appropriate patients for prophylactic therapy.
Calcium channel blockers, βblockers, serotonin antagonists, antidepressants, antihis tamine mimetics, and antiepileptic drugs have been prescribed for migraine prophylaxis. Among these drugs, antiepileptic drugs, especially topiramate (TPM), are most frequently prescribed for children and adolescents. However, TPM should be used cautiously, parti cularly in pe diatric patients, because TPM has several side effects: weight loss, hypohi drosis, paresthesia, dizziness, kidney dysfunction, ataxia, acute myopia, and secondary angle closure glaucoma. TPM also can cause cognitive dysfunction, including language disturbances in patients with epilepsy when administered at the recommended dose 48) . Several reports suggest that low dose TPM may lead to language disturbances in adult patients with migraine 911) . How ever, there are no published reports investigating the effects of TPM on migraine in children. Therefore, this study aimed to veri fy the safety of lowdose TPM on language function in pediatric patients with migraine.
Materials and methods

Patients
Ninetysix pediatric patients diagnosed with migraine who need ed TPM for migraine prevention because of the frequency more than 4 times per week were enrolled at the Department of Pediatrics of Chonbuk National University Hospital from May, 2011 to January, 2016. All patients received TPM monotherapy and were excluded when taking any medications which altered language function during followup. Brain magnetic resonance imaging and electro encephalography were examined to rule out secondary headaches and standard language tests were performed 2 times at minimum, at least 3 months apart. 30 patients were en rolled for this study after 66 patients were excluded. 58 pati ents excluded because of incomplete data and eight patients who needed other prophylac tic medications for migraine were exclud ed. Bilingual patients were not included.
Methods
All patients were assessed at least twice using standard lan guage tests: The first language test was administered just prior to TPM treat ment and the second test after at least 3 months of TPM therapy. We used the Korean versions of the language tests because all the patients exclusively spoke Korean. The average followup period was 4.3±2.7 months.
The starting dose of TPM was 25 mg/day at bed time, and then was increased up to 100 mg/day or 1 mg/kg/day. The mean dosage was 0.9 mg/kg/day.
This study was performed with approval from the Institutional Review Board of Chonbuk National University Research Council (CUH 201407008).
Language tests
1) Test of Language Problem Solving Abilities
TOPs is an evaluation tool that measures metalinguistic skills of transforming logical thinking to language in children between the ages of 5 and 12 years. The illustrations used in this test were de veloped by the Seoul Community Rehabilitation Center, Repu blic of Korea 12, 13) . The TOPS is divided into 3 categories and contains a total of 17 illustrated materials. The first category consists of 18 questions about determining cause, including interrogative, "Why" ques tions (determining cause). The second category consists of 20 questions about problem solving, including "How" questions (making infer ence).
Finally, the third category consists of 12 questions about mak ing predictions, including answers to questions such as "How do you know?" and "What happens?" (making predictions). Scores ranging from 0 to 2 were assigned depending on responses to each cate gory, with a top score of 100. Answers were recorded and docu mented immediately after the tests were completed. Scores were defined as raw scores, mean scores, and total scores for each cate gory. The length of articulation for each answer was compared using the mean length of utterance in words (MLUw), which is de fined as the mean score of the length of articulation obtained by adding all the words in the answer divided by the number of sen tences included in the answer 13) .
2) Korean version of the Receptive & Expressive Vocabulary Test
The Receptive & Expressive Vocabulary Test (REVT) is a stand ardized test that is approved for evaluation of receptive and expres sive vocabulary development and is applicable to children from 2 years old to adult 14) . Raw scores were calculated based on basal and ceiling results, and equivalent ages were also measured 14) .
3) Urimal test of articulation and phonology
The Urimal test of articulation and phonology (UTAP; Urimal means Korean language) is a test designed for individuals with abnormal articulation that have a systematic approach in solving articulation problems by examining their pronunciation in a single vocabulary or in a sentence. The test, designed for pati ents from 2 to 12 years old, presents a certain picture to the children and leads them to make a sentence which includes a targeted phoneme. Ac curacy is calculated by dividing the number of in correct phonems by the total number of phonems and is expres sed as percent cor rect 15) .
4) CSL analysis
The computerized speech laboratory (CSL) is an acoustic analy sis system with robust hardware for data acquisition, comple mented by a versatile suite of software available for spee ch analy sis, teachi Korean J Pediatr 2017;60(7):227-231 ng, research, voice measurement, clinical feedback, acoustic phonetics, and forensic work. The equipment al lows for the simultaneous capture of microphonic and laryngographic signals. The individual is asked (after an adequate training) to emit a sustained /a/,/e/,/i/,/o/,/u/ and a short sentence. The standard deviations of the intensity and frequency of the sentence (expressed as the percentage of to the mean value) were obtained.
Statistical analysis
Statistical significance was determined analyzed using IBM SPSS version 22.0 for Windows (SPSS Inc., Chicago, IL, USA). Paired t tests were used to compare differences before and after TPM treat ment. All values are expressed as mean±standard deviation. The value P<0.05 was considered significant.
Results
The mean age of patients was 144.1±42.3 months (male:female ratio=1:2.3).
Patients did not change drugs, and completed all followup language tests during the study period.
Twenty patients responded well to the treatment, and patients' migraine was reduced after taking TPM. There were 5 patients who showed no significant differences in in headache frequency or headacherelated disability. In 5 patients, the migraine was ag gravated. Among of these 5 patients, 3 patients had a medi cation change after the second language test was completed.
Results of the TOPS
The language parameters of TOPs were changed after TPM treatment; however, it was not statistically significant. The highest score in the "Determine cause" category was 22. There was no significant difference between baseline (15.0±4.4) and TPM treat ment scores (15.4±4.8, P>0.05) ( Table 1 ). The highest score in the "making inference" category was 30. The mean score at baseline was 17.7±5.6 and 17.6±6.6 after TPM treatment; this difference was also not significant (P>0.05) ( Table 1) .
The highest score in the "Predicting" category was 20. The mean score of 11.5±4.5 was obtained for pediatric migraine pati ents before TPM treatment, which increased to 12.3±4.0 after taking TPM. Moreover, this value was not significant (Table 1 ) (P> 0.05).
Total score of TOPs which differences before and after TPM monotherapy was not significant (Table 1 ) (P>0.05). Of a maxi mum score of 100, the mean score of patients before taking TPM was 44.1±13.5, which increased to 45.3±13.6 after taking TPM.
MLU-w in TOPS
The total mean length of utterance in words (MLUw) during the test decreased from 5.5±2.0 to 4.9±1.5 after TPM treatment (Table 2 ) (P<0.05).
The difference in MLUw for the "determine cause" category of questions before and after TPM treatment was significant, de creasing from 5.5±1.7 to 4.3±1.3 (Table 2 ) (P<0.05).
With respect to "making inference" the mean MLUw score de creased 6.2±2.1 to 4.6±1.5 (P<0.05) after taking TPM. However, the "predicting" category of the mean MLUw score decreased from 5.5±2.3 to 4.3±1.8 after TPM treatment; however, it was not signi ficant (Table 2 ) (P>0.05).
Results of the REVT
REVT did not change significantly. In the Receptive Vocabulary Test, the mean score of 97.8±22.1 was obtained for patients with pediatric migraine before TPM treatment, which decreased to 96.3±20.0 after taking TPM. In addition, Expressive Vocabulary Test was 81.8±23.4 to 82.3±25.4 months. In the control group, the Receptive Vocabulary Test was 112.5±17.9 and Expressive Voca bulary Test was 94.1±9.3 (P>0.05).
Result of U-TAP
UTAP has not been shown any specific change. When we com pare the groups premedication and postmedication, there was no damage found in articulation and phonology validation in both groups and control group which have 100%.
The mean score of pitch test increased from 209.8±27.9 to 211.3 ±34.6 after TPM treatment (P>0.05). In the energy test, the mean score of 58.6±7.4 was obtained for pediatric patients with mig raine before TPM treatment, which increased to 59.5±6.6 after taking TPM. For parameter pitch and energy, there was no signifi cant in fluence on the data from the measuring between the groups. There was no corresponding significant influence of medication for both . In our study, we analyzed the effects of TPM on language development using a set of specific language evaluation tools. Pediatric patients with migraine with no history of anticonvulsant medication were evaluated on the basis of language characteristics before and after TPM medication using TOPs, MLUw, REVT, U TAP, and CSL prospective analysis throughout the study.
The TOPs was used to examine problemsolving ability, which refers to the ability to comprehend the causes of events, speculate on conditions, and solve problems 13) . There was no significant difference in language problemsolving skills before and after TPM treatment. The mean "determine cause" score declined in 13 of 30 patients (43.3%) after TPM, the mean "making inference" score declined in 16 of 30 patients (53.3%), and the mean "pre dicting" score was reduced in 14 of 30 patients (46.6%). In the MLUw por tion of the TOPs, the mean "determine cause" score decreased from 5.5 to 4.3, the mean "making inference" score de creased from 6.2 to 4.6, and the mean "predicting" score de creased from 5.5 to 4.3 fol lowing TPM treatment. Similarly, the total problemsolving MLUw score decreased from 5.5 to 4.9 after TPM treatment. These results show that TPM treatment may cause vocabulary function impair ment in problem solving and deterioration of speaking sufficient sentences. After TPM medica tion, the answers of the exa minees appeared to become more ambiguous, were phrased in shorter sen tences, and were delayed because of difficulties in word choice selection. Further more, improper grammar was used in some cases. This suggests that attention is required when TPM is used in pedi atric migraine patients.
The REVT was used as a tool for comparative analysis of recep tive vocabulary development skills, which encompasses the ability to see, hear, and understand linguistic stimuli 13) . Receptive voca bulary test and expressive vocabulary test were compared before and after TPM monotherapy in our study. Although 12 of 30 pati ents' score was decreased in the receptive vocabulary test and 8 of 30 patients' score was decreased in the expressive vocabulary test, REVT was not significant.
In addition, the results of UTAP remained unchanged. In CSL analysis, all correlations were not significant. This study has several limitations. First, this study lacked lan guage evaluation tools. Second, it was conducted at a single cen ter with a smaller subject group. Finally, larger studies are requir ed to evaluate the longterm efficacy, optimal dose, length of treatment, and longterm effects of TPM. Future studies could be considered with positive effects of language development after reductions in migraine headache.
In conclusion, our results show that TPM is effective in the pre vention of migraine headache and in reducing the severity of the attack. Furthermore, we found no difference with the ability of pitch and energy.
Result of CSL analysis
In addition, for parameter vowel (in Korean /a/,/i/,/u/,/e/,/o/), there was no significant influence on the data obtained from the groups. These results did not yield a significant correlation between the data of both before and after medication of vowel (Table 3 ) (P> 0.05).
Discussion
Although TPM was initially developed for the treatment of epile psy, it is an effective migraine preventive therapy in adults, as demonstrated in several studies 16, 17) . The doses of TPM required to treat migraine are lower than those needed to treat epilepsy, result ing in a lower prevalence of adverse effects 18) . Treatment options for pediatric migraine are particularly limited, and there are few mi graine preventive agents approved for use in child ren 19, 20) . Thus, preventive pharmacologic treatments for mig raine in children need to be based on efficacy and safety. Precisely how TPM prevents migraine is unclear; however, generally, it appears to reduce the geneticallyderived headache that provokes mi graine attacks in susceptible individuals.
Fallah et al. 21) showed TPM as a safe and effective drug for pe diatric migraine prophylaxis, which reduces monthly frequ ency, severity, duration, and disability of migraine in children. Other studies have shown that TPM at 100 mg/day is effective in the pre vention of migraine headaches and in reducing the se verity of the attack 2224) . Similarly, the present study showed that TPM is effective 
